Built on Decadesof Research

Built by a team that has published hundreds of peer-reviewed studies with tens of thousands of citations across addiction science, digital intervention, and cannabis research, and funded by the National Institutes of Health.

Reasons for Taking a Break
Days Using Before Break
Clear30 Research Statistics

Funded by the National
Institutes of Health

Clear30 was built with a competitive NIH/NIDA SBIR grant. We've completed Phase 1, which included building the core app and developing an adolescent version. The same research team continues to guide the product today.

What We Measure

01

Engagement

How often users show up and stick with it

02

Outcomes

Changes in behavior or wellbeing

03

Real-World Use

How people apply it outside the app

Who We Reach

Who We Reach

The first of many publications on Clear30

Russell, A. M., Acuff, S. F., Muench, F. J., & Bergman, B. G. (2025). Characterizing users of a mobile application for supporting a 30-day break from cannabis. Psychology of Addictive Behaviors, 39(6), 571–576.

https://doi.org/10.1037/adb0001075

Scientific and Clinical Advisors

  • Clear30's advisory leadership provides expert guidance across addiction science, clinical care, public health policy, and behavior change.
  • These advisors help ensure Clear30 is developed and evaluated in ways that align with established research, real-world clinical practice, and the needs of institutions supporting student and young adult well-being.
  • Their involvement strengthens Clear30 as a responsible, evidence-informed partner for universities and health organizations.
Contact our team
Dr. Fred Muench - Clear30 Scientific and Clinical Advisors

Advisory Leadership

  • A. Thomas McLellan

    A. Thomas McLellan, PhD

    Creator of the Addiction Severity Index and former U.S. Deputy Director of National Drug Control Policy, with decades of experience shaping addiction treatment standards and national policy.

  • Stephen D'Antonio

    Stephen D'Antonio

    Former Executive Vice President at Shatterproof, trained in evidence-based family treatment approaches and large-scale behavioral health program implementation.

  • Kamala Génecé

    Kamala Génecé

    Chief Clinical Officer at Behavioral Health Group, focused on clinical implementation of evidence-based behavioral health supports across care settings.

  • Lauren Johnson

    Lauren Johnson

    Marketing Director at Fors Marsh, specializing in public health communications, behavior change messaging, and large-scale health campaigns.

  • Marcia Lee Taylor

    Marcia Lee Taylor

    Founder of MLT Strategies to reduce opioid overdoses, former EVP Head of Policy at Partnership to End Addiction.

  • Alan Budney

    Alan Budney, PhD

    Leading researcher in cannabis use disorder, developer of evidence-based behavioral treatments for cannabis dependence, and Professor at Dartmouth's Geisel School of Medicine.

Some of Dr. Muench's Publications

Fred Muench

Fred Muench, PhD